Literature DB >> 4197209

Myasthenia gravis. Cellular response to basic myelin protein compared with cellular and humoral immunity to muscle antigens.

E Kott, A H Rule.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4197209     DOI: 10.1212/wnl.23.7.745

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  8 in total

1.  Myasthenic decrement and myasthenic myopathy. A study on the effects of thymectomy.

Authors:  P Pinelli; A Arrigo; A Moglia
Journal:  J Neurol Neurosurg Psychiatry       Date:  1975-06       Impact factor: 10.154

2.  Cellular immune response to acetylcholine receptor-rich fraction, in patients with myasthenia gravis.

Authors:  O Abramsky; A Aharonov; C Webb; S Fuchs
Journal:  Clin Exp Immunol       Date:  1975-01       Impact factor: 4.330

3.  Anti-CNS antibodies in neurological and psychiatric disorders.

Authors:  A V Plioplys; J Thibault; J P Bouchard; C Cockburn; R Hawkes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-11       Impact factor: 10.154

Review 4.  Progress in myasthenia gravis.

Authors:  C W Havard
Journal:  Br Med J       Date:  1977-10-15

5.  Multiple sclerosis associated with defective neuromuscular transmission.

Authors:  W Cendrowski
Journal:  J Neurol       Date:  1975-08-01       Impact factor: 4.849

6.  Myasthenia gravis: studies on HL-A antigens and lymphocyte subpopulations in patients with myasthenia gravis.

Authors:  L Hammarström; E Smith; E Möller; C Franksson; G Matell; G Von Reis
Journal:  Clin Exp Immunol       Date:  1975-08       Impact factor: 4.330

7.  Role of thymectomy in the surgical treatment of myasthenia gravis.

Authors:  K Konomi; S Toyoda; F Nishikata; S Saito; H Yamamoto; M Torisu; S Kawanami
Journal:  Jpn J Surg       Date:  1979-03

8.  Immunological relationship between acetylcholine receptor and thymus: a possible significance in myasthenia gravis.

Authors:  A Aharonov; R Tarrab-Hazdai; O Abramsky; S Fuchs
Journal:  Proc Natl Acad Sci U S A       Date:  1975-04       Impact factor: 11.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.